{"id":17857,"date":"2014-04-05T11:30:00","date_gmt":"2014-04-05T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/case-farmaceutiche-quanto-guadagna-big-pharma-sulla-nostra-malattia\/"},"modified":"2014-04-05T11:30:00","modified_gmt":"2014-04-05T09:30:00","slug":"case-farmaceutiche-quanto-guadagna-big-pharma-sulla-nostra-malattia","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/case-farmaceutiche-quanto-guadagna-big-pharma-sulla-nostra-malattia\/","title":{"rendered":"Pharmaceutical companies: how much does Big Pharma make on our disease?"},"content":{"rendered":"

\"\"<\/span><\/b><\/p>\n

Of Dominic De Felice<\/font><\/a> | 5<\/font><\/a> April 2014<\/font><\/a> \"Il<\/span><\/b><\/p>\n

Just a month agoAntitrust<\/span><\/strong> ruled by imposing a fine of 180 million euros jointly on two drug multinationals, Novartis<\/span><\/strong> And Roche<\/span><\/strong><\/font><\/a>, hypothesizing a cartel agreement to make use of a drug equal to another in ophthalmology but with an initial cost 70 times greater. But how much does he earn Big Pharma<\/span><\/strong> about our diseases?<\/p>\n

<\/span><\/p>\n

I have been informed that in the field of anticancer drugs, and specifically those used for bone metastases of primary tumors in other organs, there are increases (euro\/Kg) from the manufacturer of the active ingredient alone <\/font><\/a>Bees<\/font><\/a> <\/span><\/strong>(Active Pharmaceutical Ingredient, as the active ingredient is defined in jargon) to the finished drug more than 1,000,000 times! Considering that Big Pharma produces \u201cindependently<\/span><\/em>\u201d its active ingredients of the brands, the profit increases again: the active ingredient is zoledronic acid, whose brand name is Aclasta, incidentally Novartis, which costs 105 Euros\/Kg. which, becoming a finished drug, has a cost to the public of 111,472,000 euros\/kg.!!! <\/p>\n

<\/span><\/p>\n

But is this markup for a life-saving drug justified? Someone checks that Big Pharma does not exploit<\/p>","protected":false},"excerpt":{"rendered":"

di Domenico De Felice | 5 aprile 2014 Giusto un mese fa l’Antitrust si è pronunciata infliggendo una multa di 180 milioni di euro in via solidale a due multinazionali del farmaco, Novartis e Roche, ipotizzando un accordo di cartello per fare utilizzare in oculistica un farmaco uguale ad un altro ma con un costo …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17857","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17857"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17857\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}